Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 22, 2022, reports a significant regulatory development regarding its oncology portfolio. The filing details the withdrawal of the US marketing authorization for Blenrep (belantamab mafodotin-blmf), a treatment for relapsed or refractory multiple myeloma (RRMM).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific product regulatory status rather than a periodic financial statement.
Material Changes and Regulatory Actions
- Withdrawal of Authorization: GSK initiated the process to withdraw US marketing authorization for Blenrep following a request from the US Food and Drug Administration (FDA).
- Cause: The withdrawal stems from the DREAMM-3 phase III confirmatory trial, which did not meet the requirements for US FDA Accelerated Approval regulations.
- Patient Support: Patients currently enrolled in the Blenrep Risk Evaluation and Mitigation Strategy (REMS) program will be offered enrollment in a compassionate use program to continue treatment access.
Outlook, Management Commentary, and Risks
Management Commentary: GSK's Chief Medical Officer, Sabine Luik, stated that the company respects the FDA's approach to accelerated approval regulations. Management maintains that the benefit-risk profile of belantamab mafodotin-blmf remains favorable based on the totality of data from the DREAMM development program, noting durable clinical benefits for responders.
Future Outlook and Trials:
- GSK will continue the DREAMM clinical trial program to explore combination treatments and dosing optimization.
- Results from the DREAMM-7 and DREAMM-8 phase III trials are anticipated in the first half of 2023.
- These upcoming results are expected to inform future regulatory pathways for the drug.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2021 Form 20-F, Q3 2022 results, and the ongoing impact of the COVID-19 pandemic.
Key Facts for Investor Verification
- Confirm the immediate impact of the Blenrep withdrawal on GSK's oncology revenue projections for the remainder of 2022 and 2023.
- Verify the timeline and enrollment criteria for the compassionate use program for existing Blenrep patients.
- Monitor the design and primary endpoints of the upcoming DREAMM-7 and DREAMM-8 trials scheduled for results in H1 2023.
- Review the specific reasons cited by the FDA regarding the failure of the DREAMM-3 trial to meet Accelerated Approval requirements.